{"id":"estradiol-mustard","rwe":[{"pmid":"11022259","year":"2000","title":"Effects of synthetic bis-beta-chloroethylamine estrogen derivatives on proliferation of skin sarcoma cells.","finding":"","journal":"Bulletin of experimental biology and medicine","studyType":"Clinical Study"},{"pmid":"2158288","year":"1990","title":"Estramustine phosphate reversibly inhibits an early stage during adenovirus replication.","finding":"","journal":"Archives of virology","studyType":"Clinical Study"},{"pmid":"2580617","year":"1985","title":"Effect of estramustine phosphate on the assembly of isolated bovine brain microtubules and fast axonal transport in the frog sciatic nerve.","finding":"","journal":"Cancer research","studyType":"Clinical Study"},{"pmid":"6887875","year":"1983","title":"Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.","finding":"","journal":"Journal of steroid biochemistry","studyType":"Clinical Study"},{"pmid":"12830238","year":"1978","title":"Bioassay of Estradiol Mustard for Possible Carcinogenicity (CAS No. 22966-79-6).","finding":"","journal":"National Cancer Institute carcinogenesis technical report series","studyType":"Clinical Study"}],"tags":[{"label":"estradiol mustard","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["estradiol mustard"],"offLabel":[],"synonyms":["estradiol mustard"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Estrogen receptor","modality":"Small Molecule","drugClass":"estradiol mustard","explanation":"Imagine your body's cells have locks on them, and estradiol mustard has a key that fits into those locks. When it binds to the locks, it can turn on or off certain cellular processes, but the exact way it does this is still being studied. This process can affect how cells grow and divide, which is important for treating certain diseases.","oneSentence":"Estradiol mustard is thought to work by binding to and modifying estrogen receptors, although the exact mechanism is unclear.","technicalDetail":"Estradiol mustard is believed to act as an estrogen receptor modulator, potentially influencing gene expression and cellular signaling pathways through its interaction with estrogen receptors."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Estradiol_mustard","title":"Estradiol mustard","extract":"Estradiol mustard, also known as estradiol 3,17β-bis(4- phenyl)acetate, is a semisynthetic, steroidal estrogen and cytostatic antineoplastic agent and a phenylacetic acid nitrogen mustard-coupled estrogen ester that was never marketed. It is selectively distributed into estrogen receptor (ER)-positive tissues such as ER-expressing tumors like those seen in breast and prostate cancers. For this reason, estradiol mustard and other cytostatic-linked estrogens like estramustine phosphate have reduced toxicity relative to non-linked nitrogen mustard cytostatic antineoplastic agents. However, they may stimulate breast tumor growth due to their inherent estrogenic activity and are said to be devoid of major therapeutic efficacy in breast cancer, although estramustine phosphate has been approved for and is used in the treatment of prostate cancer."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1062","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=estradiol%20mustard","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=estradiol mustard","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Estradiol_mustard","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:04:12.598148","biosimilars":[],"competitors":[{"drugName":"estradiol","drugSlug":"estradiol","fdaApproval":"1975-07-23","patentExpiry":"Nov 21, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"estradiol cypionate","drugSlug":"estradiol-cypionate","fdaApproval":"1979-08-15","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"fulvestrant","drugSlug":"fulvestrant","fdaApproval":"2002-04-25","patentExpiry":"May 17, 2034","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"raloxifene","drugSlug":"raloxifene","fdaApproval":"1997-12-09","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"estradiol mustard","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"estradiol","brandName":"estradiol","genericName":"estradiol","approvalYear":"1975","relationship":"same-target"},{"drugId":"estradiol-cypionate","brandName":"estradiol cypionate","genericName":"estradiol cypionate","approvalYear":"1979","relationship":"same-target"},{"drugId":"fulvestrant","brandName":"fulvestrant","genericName":"fulvestrant","approvalYear":"2002","relationship":"same-target"},{"drugId":"raloxifene","brandName":"raloxifene","genericName":"raloxifene","approvalYear":"1997","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT06409390","phase":"PHASE2","title":"Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-08-14","conditions":["Metastatic Breast Cancer"],"enrollment":15,"completionDate":"2027-04"},{"nctId":"NCT03169764","phase":"PHASE1,PHASE2","title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03169777","phase":"PHASE1,PHASE2","title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":["Colorectal Cancer"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03169738","phase":"PHASE1,PHASE2","title":"QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-02","conditions":["Non-small Cell Lung Cancer"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03197584","phase":"PHASE1,PHASE2","title":"QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":["Ovarian Cancer"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03197571","phase":"PHASE1,PHASE2","title":"QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":["Urothelial Carcinoma"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT00005847","phase":"PHASE2","title":"Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2001-04-05","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT00003614","phase":"PHASE2","title":"Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-02-04","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT00027859","phase":"PHASE3","title":"Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2003-10-08","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT00055731","phase":"PHASE3","title":"Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2002-11-14","conditions":["Prostate Cancer"],"enrollment":413,"completionDate":"2022-12-31"},{"nctId":"NCT04753177","phase":"PHASE2,PHASE3","title":"The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer","status":"UNKNOWN","sponsor":"Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary","startDate":"2021-01-28","conditions":["The Neoadjuvant Therapy"],"enrollment":120,"completionDate":"2024-01-28"},{"nctId":"NCT00004054","phase":"PHASE3","title":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-01","conditions":["Prostate Cancer"],"enrollment":397,"completionDate":"2013-11"},{"nctId":"NCT00030654","phase":"PHASE3","title":"Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2002-10","conditions":["Prostate Cancer"],"enrollment":21,"completionDate":"2005-02-04"},{"nctId":"NCT02866955","phase":"PHASE2","title":"Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2011-06-15","conditions":["Breast Cancer"],"enrollment":100,"completionDate":"2015-08-28"},{"nctId":"NCT02853071","phase":"PHASE2","title":"Efficacy and Safety of Estracyt® in Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-01","conditions":["Breast Cancer"],"enrollment":0,"completionDate":"2020-01"},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":["Breast Cancer Organoids"],"enrollment":300,"completionDate":"2021-12-15"},{"nctId":"NCT02560051","phase":"PHASE2","title":"Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2015-11","conditions":["Prostatic Neoplasms"],"enrollment":19,"completionDate":"2017-09-14"},{"nctId":"NCT02494713","phase":"PHASE2","title":"Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2015-10","conditions":["Prostate Cancer"],"enrollment":4,"completionDate":"2017-09-14"},{"nctId":"NCT00002855","phase":"PHASE3","title":"Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1996-08","conditions":["Prostate Cancer"],"enrollment":306,"completionDate":"2005-06"},{"nctId":"NCT00038246","phase":"PHASE1,PHASE2","title":"Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2000-10","conditions":["Prostate Cancer"],"enrollment":40,"completionDate":"2004-12"},{"nctId":"NCT00165399","phase":"PHASE2","title":"Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2004-03","conditions":["Adenocarcinoma of the Prostate","Prostate Cancer"],"enrollment":62,"completionDate":"2005-12-31"},{"nctId":"NCT00005810","phase":"PHASE2","title":"Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2000-03","conditions":["Prostate Cancer"],"enrollment":40,"completionDate":"2006-06"},{"nctId":"NCT00016913","phase":"PHASE2","title":"Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-05","conditions":["Prostate Cancer"],"enrollment":34,"completionDate":"2008-05"},{"nctId":"NCT00052845","phase":"PHASE2","title":"Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-11","conditions":["Prostate Cancer"],"enrollment":80,"completionDate":"2009-04"},{"nctId":"NCT00003584","phase":"PHASE2","title":"Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"1998-07","conditions":["Kidney Cancer"],"enrollment":35,"completionDate":"2000-12"},{"nctId":"NCT00024167","phase":"PHASE3","title":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-04","conditions":["Prostate Cancer"],"enrollment":265,"completionDate":""},{"nctId":"NCT00151073","phase":"PHASE2","title":"Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2002-04","conditions":["Hormone-Refractory Prostate Cancer"],"enrollment":28,"completionDate":"2007-09"},{"nctId":"NCT00151086","phase":"PHASE1,PHASE2","title":"Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2001-12","conditions":["Prostate Cancer"],"enrollment":33,"completionDate":"2006-08"},{"nctId":"NCT00151060","phase":"PHASE2","title":"Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"1998-12","conditions":["Prostate Cancer"],"enrollment":28,"completionDate":"2006-06"},{"nctId":"NCT00183924","phase":"PHASE2","title":"Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2001-03","conditions":["Prostate Adenocarcinoma"],"enrollment":20,"completionDate":"2008-12"},{"nctId":"NCT00002721","phase":"PHASE1","title":"Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"1995-03","conditions":["Prostate Cancer"],"enrollment":18,"completionDate":"2013-06"},{"nctId":"NCT00004001","phase":"PHASE3","title":"S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1999-10","conditions":["Prostate Cancer"],"enrollment":770,"completionDate":"2007-01"},{"nctId":"NCT01250717","phase":"PHASE2","title":"Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2001-01","conditions":["Prostate Cancer"],"enrollment":28,"completionDate":"2011-05"},{"nctId":"NCT00002775","phase":"PHASE1,PHASE2","title":"Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Herbert Irving Comprehensive Cancer Center","startDate":"1998-02","conditions":["Prostate Cancer"],"enrollment":37,"completionDate":""},{"nctId":"NCT00003066","phase":"PHASE2","title":"Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Herbert Irving Comprehensive Cancer Center","startDate":"1997-02","conditions":["Breast Cancer"],"enrollment":40,"completionDate":""},{"nctId":"NCT00003717","phase":"PHASE2","title":"Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"St. Barnabas Medical Center","startDate":"1998-10","conditions":["Prostate Cancer"],"enrollment":17,"completionDate":""},{"nctId":"NCT00003633","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer","status":"UNKNOWN","sponsor":"Herbert Irving Comprehensive Cancer Center","startDate":"1998-08","conditions":["Prostate Cancer"],"enrollment":12,"completionDate":""},{"nctId":"NCT00005627","phase":"PHASE1","title":"Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"1999-03","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":"2003-04"},{"nctId":"NCT00028769","phase":"PHASE2","title":"S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-12","conditions":["Prostate Cancer"],"enrollment":41,"completionDate":"2011-07"},{"nctId":"NCT00021372","phase":"PHASE2","title":"Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"1996-02","conditions":["Lymphoma"],"enrollment":25,"completionDate":"2006-09"},{"nctId":"NCT00084565","phase":"PHASE2","title":"Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer","status":"WITHDRAWN","sponsor":"Fox Chase Cancer Center","startDate":"2003-11","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":"2004-11"},{"nctId":"NCT00003394","phase":"PHASE1,PHASE2","title":"Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1998-04","conditions":["Prostate Cancer"],"enrollment":18,"completionDate":"2003-04"},{"nctId":"NCT00025194","phase":"PHASE1,PHASE2","title":"Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-07","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":"2006-07"},{"nctId":"NCT00016107","phase":"PHASE2","title":"Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-06","conditions":["Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer","Stage IV Prostate Cancer"],"enrollment":72,"completionDate":""},{"nctId":"NCT00712452","phase":"NA","title":"Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-06","conditions":["Infertility"],"enrollment":19,"completionDate":"2009-06"},{"nctId":"NCT00046826","phase":"PHASE2","title":"Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy","status":"COMPLETED","sponsor":"Nuvance Health","startDate":"2001-09","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":"2009-10"},{"nctId":"NCT00014352","phase":"PHASE2","title":"Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-09","conditions":["Prostate Cancer","Thromboembolism"],"enrollment":0,"completionDate":""},{"nctId":"NCT00005048","phase":"PHASE1","title":"Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1997-04","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT00038168","phase":"PHASE1,PHASE2","title":"Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2000-06","conditions":["Prostate Cancer"],"enrollment":14,"completionDate":"2003-01"},{"nctId":"NCT00003084","phase":"PHASE2","title":"Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1997-12","conditions":["Prostate Cancer"],"enrollment":75,"completionDate":"2002-11"},{"nctId":"NCT00083005","phase":"PHASE2","title":"Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2004-03","conditions":["Prostate Cancer"],"enrollment":60,"completionDate":"2007-12"},{"nctId":"NCT00193271","phase":"PHASE2","title":"Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2004-08","conditions":["Prostate Cancer"],"enrollment":30,"completionDate":"2007-05"},{"nctId":"NCT00004105","phase":"PHASE1,PHASE2","title":"Combination Chemotherapy in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1998-09","conditions":["Leukemia","Lymphoma","Sarcoma","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":0,"completionDate":""},{"nctId":"NCT00705822","phase":"PHASE3","title":"Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2006-08","conditions":["Prostatic Neoplasms"],"enrollment":54,"completionDate":"2009-07"},{"nctId":"NCT00193193","phase":"PHASE2","title":"Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2000-08","conditions":["Prostate Cancer"],"enrollment":100,"completionDate":"2007-02"},{"nctId":"NCT00176527","phase":"PHASE2","title":"Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy","status":"TERMINATED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2002-11","conditions":["Prostate Cancer"],"enrollment":40,"completionDate":"2007-08"},{"nctId":"NCT00541281","phase":"PHASE2","title":"Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2003-12","conditions":["Hormone Resistant Prostate Cancer","Metastatic Prostate Cancer"],"enrollment":150,"completionDate":"2006-02"},{"nctId":"NCT00132756","phase":"PHASE1,PHASE2","title":"Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Morton Plant Mease Health Care","startDate":"2003-12","conditions":["Prostate Cancer"],"enrollment":30,"completionDate":""},{"nctId":"NCT00218205","phase":"PHASE2","title":"A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer","status":"UNKNOWN","sponsor":"Department of Veterans Affairs, New Jersey","startDate":"2002-07","conditions":["Prostate Cancer"],"enrollment":28,"completionDate":"2006-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"GEO3F3A4K1","UMLSCUI":"C0059620","ChEMBL_ID":"CHEMBL1697793","PUBCHEM_CID":"31586","MESH_SUPPLEMENTAL_RECORD_UI":"C023758"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":14,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2000 Jun","pmid":"11022259","title":"Effects of synthetic bis-beta-chloroethylamine estrogen derivatives on proliferation of skin sarcoma cells.","journal":"Bulletin of experimental biology and medicine"},{"date":"1990","pmid":"2158288","title":"Estramustine phosphate reversibly inhibits an early stage during adenovirus replication.","journal":"Archives of virology"},{"date":"1985 May","pmid":"2580617","title":"Effect of estramustine phosphate on the assembly of isolated bovine brain microtubules and fast axonal transport in the frog sciatic nerve.","journal":"Cancer research"},{"date":"1983 Jul","pmid":"6887875","title":"Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.","journal":"Journal of steroid biochemistry"},{"date":"1978","pmid":"12830238","title":"Bioassay of Estradiol Mustard for Possible Carcinogenicity (CAS No. 22966-79-6).","journal":"National Cancer Institute carcinogenesis technical report series"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"estradiol mustard","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Estradiol mustard is a small molecule drug in the estradiol mustard class, but specific details about its development, ownership, and commercial status are not available. Its target and mechanism of action are also unknown. As a result, there is limited information available about its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to determine its clinical utility and safety profile. Without more information, it is difficult to assess its commercial status or key safety considerations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}